Sustained use of GLP-1 therapies (a class of medications used to manage Type-2 diabetes) can significantly reduce medical cost growth over the long term for employers and improve workforce health outcomes, according to the latest report by Aon.
If you are already a subscriber
OR sign-up for a trial access here
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
more »